Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Savolitinib Alone and with Famotidine in Healthy Subjects
NCT04179071Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of savolitinib in solid tumor (2 arms), sponsored by AstraZeneca. Primary endpoints: Maximum observed plasma concentration (Cmax) ratio and Area under plasma concentration-time curve from zero to infinity (AUC) ratio. Started Dec 2019; status: completed.
02
Drugs
savolitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04179071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04179071.